Medications

Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them.

Read our quick round-up of the LEAD trials of the daily injectable GLP-1 receptor agonist liraglutide in people with type 2 diabetes.

Read our quick round-up of the GetGoal trials of the daily injectable GLP-1 receptor agonist lixisenatide in people with type 2 diabetes.

Read our Hot Topic Review for a rapid update on the successes and failures of immunotherapies in people with or at high risk for type 1 diabetes.

Shehla Shaikh shares her experience and offers practical advice to help people with type 2 diabetes safely navigate the fasting and feasting of Ramadan. 

We round up the medications currently approved for treating type 2 diabetes in children and adolescents and look at what agents are coming through clinical trials.

Read our quick round-up of the DURATION trials of the weekly formulation of the GLP-1 receptor agonist exenatide in people with type 2 diabetes.

Read our quick round-up of the AWARD trials of the GLP-1 receptor agonist dulaglutide in people with type 2 diabetes.

John Wilding highlights the issue of hyperglycemia triggered by use of high-dose steroids and discusses management strategies.

Sanjay Kalra explains how use of alpha-glucosidase inhibitors in people with type 2 diabetes can complicate the treatment of hypoglycemia.

Nephrologist Ian de Boer joins primary care physician Amrit Lamba to discuss how the recent approval of finerenone and extension of the dapagliflozin label is likely to influence the treatment of kidney disease in people with type 2 diabetes.

Stefan Bornstein provides an overview of the current understanding about COVID-19 and diabetes, including medications, vaccines, and the impact of SARS-CoV-2 infection on diabetic ketoacidosis.

Domenica Rubino discusses the chronicity of obesity, and how STEP 4 demonstrates the need for long-term semaglutide treatment to avoid weight regain (5:59).

Ildiko Lingvay discusses the STEP 2 findings, and why a higher semaglutide dose may be optimal for most people with type 2 diabetes (8:06).

Thomas Wadden explains the rationale behind STEP 3 trial, and why semaglutide is the “breakthrough people with overweight and obesity have been waiting for.” (7:41)

Read our round-up of the STEP phase 3 trials of semaglutide 2.4 mg in people with obesity, plus the SELECT cardiovascular outcomes trial.

Lead author of the STEP 1 trial, John Wilding, discusses the findings and what they may mean for the treatment of people with obesity (5:42)

Deepak Bhatt discusses the performance of sotagliflozin in trials focusing on acute heart failure and on chronic kidney disease (11:56).

Read our overview of the SURPASS trials of the dual GLP-1/GIP receptor agonist tirzepatide in people with type 2 diabetes, plus the SURMOUNT trials in people with obesity.